Hemopurifier device in patients with solid tumours who have stable or progressive disease while on a treatment that includes pembrolizumab or nivolumab: protocol for an Australian safety, feasibility and dose-finding study

Authors

Nyan Y. Khin (ORCID: https://orcid.org/0000-0002-1412-8123)
Michael P. Brown (ORCID: https://orcid.org/0000-0002-5796-1932)
John H. Shin (ORCID: https://orcid.org/0000-0001-7490-8108)
Georges E. Grau (ORCID: https://orcid.org/0000-0002-0442-0462)
S. Clarke
Jagadeesh Kurtkoti (ORCID: https://orcid.org/0000-0002-2711-6623)
Steven P. LaRosa (ORCID: https://orcid.org/0000-0002-0773-2816)
Rosalia de Necochea Campion (ORCID: https://orcid.org/0009-0004-0148-2686)
Alessio Bloesch
CA Pollock
Kelly Edinburg
P Toby Coates
Marco Matos

Institutions

Griffith University (AU)
The University of Sydney (AU)
Royal Adelaide Hospital (AU)
Loma Linda University (US)
Royal North Shore Hospital (AU)
Gold Coast Hospital (AU)
Burwood Hospital (NZ)
Flinders Private Hospital (AU)
Aethlon Medical (United States) (US)
Keogh Institute for Medical Research (AU)
Centre for Cancer Biology (AU)
ResMed (Australia) (AU)
Institute of Infection and Immunity (CA)
The University of Adelaide (AU)

Publication Details

Journal: BMJ Open
Published: 2026-01-01
DOI: https://doi.org/10.1136/bmjopen-2025-102581
Primary Topic: Extracellular vesicles in disease
Type: article
Field-Weighted Citation Impact: 0.00

Funders

Royal Adelaide Hospital

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Hemopurifier device in patients with solid tumours who have stable or progressive disease while on a treatment that includes pembrolizumab or nivolumab: protocol for an Australian safety, feasibility and dose-finding study

Nyan Y. Khin, Michael P. Brown, John H. Shin, Georges E. Grau et al.

Jan 1, 2026

BMJ Open

Extracellular vesicles in disease

article

Hemopurifier device in patients with solid tumours who have stable or progressive disease while on a treatment that includes pembrolizumab or nivolumab: protocol for an Australian safety, feasibility and dose-finding study

Nyan Y. Khin, Michael P. Brown, John H. Shin, Georges E. Grau, S. Clarke, Jagadeesh Kurtkoti, Steven P. LaRosa, Rosalia de Necochea Campion, Alessio Bloesch, CA Pollock, Kelly Edinburg, P Toby Coates, Marco Matos

January 1, 2026article en

Abstract

No abstract available for this paper.

BMJ OpenVol. 16(1)

Griffith University (AU), The University of Sydney (AU), Royal Adelaide Hospital (AU), Loma Linda University (US), Royal North Shore Hospital (AU), Gold Coast Hospital (AU), Burwood Hospital (NZ), Flinders Private Hospital (AU), Aethlon Medical (United States) (US), Keogh Institute for Medical Research (AU), Centre for Cancer Biology (AU), ResMed (Australia) (AU), Institute of Infection and Immunity (CA), The University of Adelaide (AU)

Royal Adelaide Hospital

Good health and well-being

Openalex Percentile: Top 94%

Extracellular vesicles in disease

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Hemopurifier device in patients with solid tumours who have stable or progressive disease while on a treatment that includes pembrolizumab or nivolumab: protocol for an Australian safety, feasibility and dose-finding study — Nyan Y. Khin, Michael P. Brown, et al. · BMJ Open (2026) | TGRS Research Map | TGRS